PIK3CA
The firm is seeing the fruit of a two-year investment in transitioning from a research lab to a clinical focus.
Matched Therapy 'Evidence Scale' Predicts Targeted Treatment Efficacy in Breast Cancer Patients
With data from the SAFIR02-BREAST trial, researchers found patients with ESCAT I/II genomic alterations had longer progression-free survival when receiving a targeted therapy.
Breast Cancer Study Shows Number of Mutated PIK3CA Alleles Affects Tumor Aggressiveness
Studies in breast tumors revealed a "biphasic" relationship between mutant PIK3CA allele dosage and stem cell-like features as well as aggressiveness.
Roche Nabs CE Mark for PIK3CA Test for Breast Cancer
The PCR-based test detects mutations in the PIK3CA gene that can cause cells to grow uncontrollably, possibly leading to cancer.
Mutations in FOXA1 Gene Can Affect Breast Cancer Patients' Response to Therapy
A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and
Feb 3, 2020
Qiagen Obtains CE Mark for PIK3CA Mutation Assay
Oct 30, 2018
Precision Oncology Highlights From ESMO 2018
Jun 3, 2018
Apr 14, 2011